A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

AIMS: The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin–angiotensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are used in the vast majority of patients with HF with preserved ejection f...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur Heart J
Glavni autori: Vaduganathan, Muthiah, Jhund, Pardeep S, Claggett, Brian L, Packer, Milton, Widimský, Jiri, Seferovic, Petar, Rizkala, Adel, Lefkowitz, Martin, Shi, Victor, McMurray, John J V, Solomon, Scott D
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Fast Track Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327532/
https://ncbi.nlm.nih.gov/pubmed/32221596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa184
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items